iPSC

Biologists have published a DIY recipe for human induced pluripotent stem cell maintenance, which they estimate costs 3 percent of commercial media prices.

To advance the possibility of off-the-shelf cardiac cell therapies, scientists devise an engineered cardiac stem cell that avoids stimulating a detrimental immune attack.

Dropping the transcription factor from the four so-called Yamanaka factors reduces the efficiency of inducing the production of stem cells, but the resulting cells are of greater quality.

The patient’s vision has improved since the procedure, and her cornea remains clear.

The cells, derived from induced pluripotent stem cells, are in testing as an immunotherapy for cancer patients with solid tumors.

Many researchers see the move to relax the rules as a welcome change, yet some are worried the revisions don’t take public concerns enough into consideration.

Uncertainties about the cells’ risk profiles and the potential for hyping unproven therapies mean scientists and the media must tread carefully.

The treatment will be tested in a handful of patients who suffered nerve damage in sports or traffic accidents.

From disastrous scientific setbacks to the upending of scientific dogma and the end of a 40-year search for a protein

Since their discovery in 2006, induced pluripotent stem cells have been poised to reprogram regenerative medicine. Twelve years on, here’s how far they’ve come.

This is the first time researchers have tested the use of the reprogrammed stem cells in the human brain.

Without knowing the cells’ mechanism of action, researchers question the best way to administer them to patients.

Surgeons will inject approximately 5 million dopamine-producing progenitor cells into patients’ brains.

Stem cells and cancer cells have enough molecular similarities that the former can be used to trigger immunity against the latter.

Researchers use the technique to turn on Oct4 or Sox2 in mouse embryonic fibroblasts and convert them into pluripotent cells.